Retrograde transport of viral vectors in the rodent spinal cord provides a powerful means to administer a therapeutic transgene from the innervated musculature. With the aim of scaling up this approach to non-human primates, we have injected recombinant adeno-associated vectors (rAAV) serotype 6 expressing enhanced green fluorescent protein (eGFP) into the gastrocnemius muscle of African green monkeys to determine whether this results in efficient transgene delivery to lumbar motor neurons. Cells expressing eGFP were observed across more than 1 cm of the spinal cord 4 weeks after intramuscular injection, reaching more than half of motor neurons in some cross-sections. Furthermore, quantitative PCR on the spinal cord tissue confirmed that eGFP expression within motor neurons was due to bona fide retrograde transport of the vector genome from the muscle. Although infiltrations of macrophages and lymphocytes were observed in the rAAV2/6-injected muscle, there was no detectable immune response within the transduced region of the spinal cord. These findings imply that retrograde delivery of rAAV serotype 6 in a primate species constitutes a non-invasive and robust approach to transduce motor neurons, a crucial target cell population in neurodegenerative disorders, such as amyotrophic lateral sclerosis and spinal muscular atrophy.
Effective in vivo gene therapy will require the delivery of the transgene to sufficient numbers of target cells in a manner that is atraumatic to the tissue. Transgene delivery to the central nervous system (CNS) is particularly difficult because of the presence of the blood-brain barrier. Although the use of viral vectors has allowed sustained expression in neurons, vector administration into the CNS requires neurosurgery to deliver the vector to the target neuronal cell somata, by diffusion across a three-dimensional space usually in the range of cubic millimeters. This is clearly not applicable to devastating motor neuron disorders, such as amyotrophic lateral sclerosis and spinal muscular atrophy, which have target cells located throughout the spinal cord.
For these neurons projecting outside the CNS, it is possible to bypass the blood-brain barrier by exploiting their capacity to retrogradely transport viral particles from the periphery. Through a simple intramuscular injection, the vector can be taken up by the nerve terminals and transported along the axon to the motor neuron soma within the spinal cord. Lentiviral vectors based on the equine infectious anemia virus and pseudotyped with the rabies G envelope have been used for the delivery of therapeutic transgenes, increasing lifespan in mouse models of both amyotrophic lateral sclerosis and spinal muscular atrophy. 1, 2 Adenovirus and adeno-associated virus (AAV) have also provided functional benefits in amyotrophic lateral sclerosis mice by the retrograde transduction of motor neurons. [3] [4] [5] Adeno-associated viruses have been the first viral vectors to be used in clinical trial for CNS disorders due to their neuronal tropism, stable transgene expression in quiescent cells, low toxicity and poor rate of integration in the host genome. 6, 7 The lack of pathogenecity in humans from the wild-type virus further distinguishes them from lentivirus and adenovirus. We have recently observed efficient retrograde transport of recombinant AAV serotype 6 (rAAV2/6: rAAV serotype 2 genome packaged in the serotype 6 capsid) in mice. 8 In the present study, we examined whether rAAV2/6 retrograde transport can be scaled up to deliver a transgene to motor neurons via an atraumatic peripheral injection in a non-human primate species (depicted in Figure 1a) .
Three male African green monkeys of St. Kitts origin (Chlorocebus sabaeus, 3.06-3.30 kg) were injected with 1.3 Â 10 12 viral particles (3.3 Â 10 9 transducing units) of rAAV2/6 expressing enhanced green fluorescent protein (eGFP) into the right gastrocnemius muscle. A month later the animals were killed and the tissues were analyzed. The expression of eGFP demonstrated efficient transduction of gastrocnemius muscle compared with the contralateral uninjected muscle (Figure 1b) . This tropism for primate skeletal muscle is in accordance with observations that rAAV serotype 1, whose capsid proteins share 99.2% sequence homology with serotype 6, 9 efficiently transduces hindlimb muscles of cynomolgus macaques. 10 Macroscopic analysis of the spinal cord showed eGFP epifluorescence in the ventral roots corresponding to the efferent axons of the tibial nerve (L4 to S2) (Figure 1c ). An intense eGFP signal was observed in the ipsilateralinjected side on transverse cryosections (Figures 1d and  e) and was confined to large cell bodies and dendrites of the ventral horn. Colocalization of the eGFP signal with the motor neuron markers choline acetyltransferase and vesicular acetylcholine transporter, demonstrated that solely motor neurons were transduced (Figure 2a ). The expression of eGFP was not observed in neighboring Figure 1 Recombinant adeno-associated virus serotype 6 (rAAV2/6) is retrogradely transported from the gastrocnemius muscle to the lumbar spinal cord in African green monkeys. (a) Schematic of the experimental procedure: vector particles encoding enhanced green fluorescent protein (eGFP) are injected into the muscle, taken up at the synapse by motor neuron terminals and transported along the axons to neuronal cell bodies in the spinal cord. Single-stranded rAAV2/6 expressing eGFP under control of a hybrid construct driven by the cytomegalovirus (CMV) promoter and the human beta-globin intron (glb), was produced in 293AAV cells as described previously. 24 Cell lysates were purified on a heparin affinity column (HiTrap Heparin HP, GE Healthcare, Upsala, Sweden) and the concentrated eluate titrated by (i) real-time PCR against the vector genome sequence (viral particles) and (ii) infection of 293T cells and flow cytometry analysis 48-h post infection (transducing units). Animals were injected into the gastrocnemius muscle of the right leg with 1.3 Â Retrograde delivery of AAV to primate spinal cord C Towne et al glial cells or interneurons, nor in the upper motor neurons in the motor cortex, suggesting that rAAV2/6 had not undergone transynaptic spread. Motor neurons positive for eGFP were counted and compared with the total number of motor neurons per ipsilateral hemisphere across the breadth of the transduced region (Figure 2b) . A substantial fraction of motor neurons were eGFP-positive, with some crosssections in each spinal cord showing more than 50% of transduction. This is significant considering the presence of adjacent pools of motor neurons innervating non-injected muscles through the tibial, femoral and common fibular nerves. Furthermore, the transgene was delivered to neurons spread over 1 cm of the spinal cord longitudinal axis.
To ascertain whether eGFP expression was due to retrograde transport of viral genomes to the motor neuron nuclei, the ventral horn was dissected and the amount of vector genomes quantified by real-time PCR (Figure 3) . We measured 29.4 ± 11.4 viral genomes per host albumin copy in the ipsilateral ventral horns of the . Melting curves confirmed amplification of solely one amplicon for the albumin reaction, indicating high sequence homology between rhesus macaque and African green monkey. Increased levels of vector genome copies in the ipsilateral-injected lumbar spinal cord compared with the contralateral lumbar and the thoracic spinal cord hemispheres (n ¼ 3, *Po0.05, ANOVA, Newman-Keuls test) demonstrate that rAAV2/6 genome, and not the reporter protein (enhanced green fluorescent protein (eGFP)), was retrogradely transported from the gastrocnemius muscle.
Retrograde delivery of AAV to primate spinal cord C Towne et al lumbar spinal cord. This average number underestimates the transduction level in motor neurons because of the presence of non-transduced cells in the dissected tissue. In the contralateral side, as well as in both sides at the thoracic level, we detected a low level of vector copies (below 4.8±0.6 viral genomes per host albumin copy) (Po0.05 when compared with ipsilateral ventral horn). The increased presence of vector copies in the targeted spinal cord portion demonstrates retrograde transduction of motor neurons by rAAV2/6. The low level of detectable vector copies in non-targeted tissue (for example, the contralateral spinal cord) likely represents a vascular spread of the vector, as described previously after intramuscular injection into non-human primates. 10 Previous descriptions of rAAV retrograde transport in rodents have reported relatively lower levels of transduction than described here. Intramuscular injections of rAAV2/2 in mice have resulted in sparse transduction, although not quantified, within the spinal cord. 4, 11 Tuszynski et al. 12 have provided a comparison of the capability of rAAV serotypes 1-6 to be retrogradely delivered from the rat extensor carpi muscle. In that report, rAAV2/1 transduced approximately 120 motor neurons corresponding to a modest 4.1% of cells innervating the injected muscle, whereas rAAV2/6 resulted in transduction of o1%. In mice, we have observed levels of rAAV2/6 retrograde transport comparable to the findings of the present primate study. 8 One possible explanation for the greater level of transduction observed in this study compared with other reports may be that we have injected a relatively higher viral load to the muscle. For example, 1.3 Â 10 12 viral particles were delivered to the primate muscle, which is approximately 60 times more viral particles per weight of animal than injected into the rat extensor carpi muscle (1.0 Â 10 9 viral particles). 12 Another plausible explanation for the discrepancy may be the purification method of the vector. The rAAV2/6 produced in this study was purified from the transfected cell lysate using heparin column chromatography, whereas many laboratories routinely purify vector particles using CsCl 2 or iodixanol gradients. In contrast to density gradients, heparin columns are unlikely to enrich virus preparations for effective particles. The presence of high proportions of empty particles may therefore increase the uptake of active particles from the nerve terminal via mechanisms that remain to be elucidated. Another possibility is that the presence of non-viral protein contaminants may have contributed to the observed tropism. Indeed, it was demonstrated that the purification method and presence of contaminating proteins in vector preparations alter the tropism or rAAV2/8 for glial cells and neurons after injection into the rat brain. 13 We have examined the two vector preparations used for this study by protein gel electrophoresis and observed low levels of non-viral protein contaminants that may have accounted for the enhanced uptake from nerve terminals (Supplementary Figure 1) . Future work will be required to examine these issues more directly and determine the respective contributions of serotypes, production and purification methods in the capacity of rAAV vectors to be retrogradely transported in neurons.
As host immune responses have proven an important scale up issue from rodents to larger animals, [14] [15] [16] we have determined whether administration of the rAAV2/6 vector mediated cellular toxicity or an immune response in the monkeys. Infiltrating cells were observed in the injected muscle and corresponded to recruitment of both macrophages and T cells (Figure 4a and b) . The pattern of cellular infiltration was heterogeneous throughout the muscle. Regions of muscle with relatively low numbers of cellular infiltrates had consistent (although weak) eGFP expression within myofibers. On the other hand, regions of muscle with high levels of infiltration had myofibers predominantly devoid of the transgene with a few strongly expressing eGFP-positive myofibers interspersed (Figure 4a lower panel) . These findings suggest that elimination of transduced myofibers had occurred. This peripheral immune response to rAAV has already been well characterized. Acute immune responses and elimination of transduced myofibers after the delivery of rAAV to skeletal muscle has been observed in canine models of muscular dystrophy.
14-16 Likewise, T cell-mediated immune responses have previously been observed after rAAV2/2 delivery to non-human primate muscle. 17 This immune response to rAAV in muscle can be circumvented through longterm immunosuppression in cynomolgus macaques. 10 Next we examined whether peripheral delivery of rAAV2/6 to motor neurons evoked an immune response or cellular toxicity within the spinal cord. Cell counts within the ipsilateral and contralateral hemispheres of the spinal cord indicated that there was no motor neuron loss on the injected side (17.2 ± 0.9 motor neurons per section) compared with the uninjected side (17.9 ± 0.5 motor neurons per section) (Figure 4c ). Furthermore, neither cellular infiltration nor an upregulation of the inflammatory markers glial fibrillary acidic protein and ionized calcium binding adaptor molecule 1 was observed in the transduced hemisphere of the lumbar spinal cord compared with the contralateral ventral horn and the thoracic spinal cord (Figure 4d ). These findings are encouraging considering that intraparenchymal injections of therapeutically-relevant doses of rAAV have been shown to induce innate and adaptive immune responses in rodents and non-human primates. [18] [19] [20] Such immune responses lead to the elimination of transgeneexpressing cells and/or silencing of the transgene, and may account for the poor translation of gene therapy approaches observed in preclinical and clinical studies. 21 Indeed, eradication of rAAV2/2-transduced hepatocytes by cell-mediated immunity has been observed in a Phase I clinical trial for hemophilia. 22 Presumably the peripheral delivery described here avoids the temporary breaching of the blood-brain barrier. In addition, it prevents mechanical stress and release of viral particles in the extracellular space of the CNS, two conditions that may otherwise prime innate and/or adaptive immune responses.
In conclusion, we have demonstrated that retrograde delivery of rAAV2/6 constitutes a robust gene delivery strategy to the CNS, with potential clinical applications in gene therapy for spinal cord injury and motor neuron diseases such as amyotrophic lateral sclerosis. Considering similar body weight and dimensions of neuromuscular connections of the injected monkeys with human newborns, this technology may also be used for the replacement of the survival of motor neuron (SMN1) gene in the monogenic disorder spinal muscular atrophy, the leading cause of infant mortality. 23 Retrograde delivery of AAV to primate spinal cord C Towne et al
